- Home
- ICUI vs LGN Comparison
ICUI vs LGN Comparison
Compare ICUI & LGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICUI
- LGN
- Stock Information
- Founded
- ICUI 1984
- LGN 1963
- Country
- ICUI United States
- LGN United States
- Employees
- ICUI N/A
- LGN N/A
- Industry
- ICUI Medical/Dental Instruments
- LGN
- Sector
- ICUI Health Care
- LGN
- Exchange
- ICUI Nasdaq
- LGN Nasdaq
- Market Cap
- ICUI 3.2B
- LGN 3.1B
- IPO Year
- ICUI 1992
- LGN 2025
- Fundamental
- Price
- ICUI $140.16
- LGN $35.49
- Analyst Decision
- ICUI Buy
- LGN Strong Buy
- Analyst Count
- ICUI 6
- LGN 12
- Target Price
- ICUI $183.60
- LGN $37.54
- AVG Volume (30 Days)
- ICUI 290.1K
- LGN 824.0K
- Earning Date
- ICUI 11-06-2025
- LGN 11-14-2025
- Dividend Yield
- ICUI N/A
- LGN N/A
- EPS Growth
- ICUI N/A
- LGN N/A
- EPS
- ICUI N/A
- LGN N/A
- Revenue
- ICUI $2,320,363,000.00
- LGN $2,213,862,000.00
- Revenue This Year
- ICUI N/A
- LGN $13.22
- Revenue Next Year
- ICUI N/A
- LGN $11.87
- P/E Ratio
- ICUI N/A
- LGN N/A
- Revenue Growth
- ICUI N/A
- LGN 77.61
- 52 Week Low
- ICUI $107.00
- LGN $26.96
- 52 Week High
- ICUI $196.26
- LGN $43.82
- Technical
- Relative Strength Index (RSI)
- ICUI 73.86
- LGN N/A
- Support Level
- ICUI $116.21
- LGN N/A
- Resistance Level
- ICUI $120.60
- LGN N/A
- Average True Range (ATR)
- ICUI 4.88
- LGN 0.00
- MACD
- ICUI 1.92
- LGN 0.00
- Stochastic Oscillator
- ICUI 69.73
- LGN 0.00
About ICUI ICU Medical Inc.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.